Therapeutic effect of torasemide combined small dose dopamine on patients with refractory heart failure/ / 心血管康复医学杂志

ABSTRACT

Objective: To observe therapeutic effect of torasemide combined small dose dopamine on patients with refractory heart failure (RHF). Methods: A total of 146 RHF patients, who were treated in our hospital from Jan 2015 to Sep 2016, were selected. According to random number table, they were randomly and equally divided into torasemide group and combined treatment group (received torasemide combined small dose dopamine), both groups were treated for 7d. Left ventricular ejection fraction (LVEF), left ventricular end-diastolic dimension (LVEDd), 6min walking distance (6MWD), levels of interleukin 6 (IL-6) and tumor necrosis factorα (TNF-α) before and after treatment, and total effective rate were measured and compared between two groups. Results: Compared with before treatment, after treatment, there were significant rise in LVEF and 6 MWD, and significant reductions in LVEDd, levels of IL-6 and TNF-αin two groups, P=0. 001 all; compared with torasemide group after 7d treatment, there were significant rise in LVEF [(30. 69±4. 52) ％ vs. (36. 29±4. 86) ％]and 6MWD [(271. 21±48. 32) m vs. (322. 45±56. 34) m], and significant reductions in LVEDd [(54. 17±7. 64) mm vs. (46. 52±6. 52) mm], levels of IL-6 [(34. 65±6. 13) μg/ml vs. (26. 18±4. 53) μg/ml]and TNF-α [(50. 27±8. 74) μg/ml vs. (37. 48± 7. 04) μg/ml]in combined treatment group, P=0. 001 all. Total effective rate of combined treatment group was significantly higher than that of torasemide group (90. 4％ vs. 71. 2％, P=0. 03). Conclusion: Torasemide combined small dose dopamine can significantly reduce levels of IL-6 and TNF-α, improve cardiac function and therapeutic effect in RHF patients, which is worth extending.